Close Menu


The microRNA-based molecular diagnostics developer plans to use earnings from the sale of securities for a range of corporate purposes.

Mirna plans to use the money to lay the groundwork for its two lead drug candidates, mimics of miR-34 and an undisclosed miRNA, both of which are involved in down-regulated in cancer.

Daniel Von Hoff, Steven McKnight, Zachary Zimmerman, Eric Olson, Victor Ambros, Michael Bristow, Thomas Cech, Stephanie Dimmeler, Douglas Mann, Jeffery Molkentin

A new study from Johns Hopkins and Rosetta researchers finds the miRview NSCLC test to be effective.

The projects include studies focused on defining the mechanisms of miRNA-target interactions, uncovering the role of a specific miRNA in Caenorhabditis elegans, determining the impact of the small RNAs in brain cancer and cardiac hypertrophy.

Papers of Note: Jan 7, 2010


RNAi- and microRNA-Related Papers Published December 2009

Norgen Biotek, Drug Information Association

Researchers from Australia and the US have used genotyping, microRNA analysis, and mitochondrial and transcriptome sequencing to tackle a transmissible Tasmanian devil cancer.

The news wasn't a complete surprise given the general difficulties in measuring and interpreting blood-borne miRNA signatures, as well as the firm's own admission in September that "technical obstacles" had been stymieing its efforts to develop the screen.

"I've been absolutely blown away by the microRNA field and the way it's blossomed," University of Massachusetts Medical School researcher and Nobel laureate Craig Mello said. "There is just one story after another [showing that] microRNAs … are very critical to many aspects of either disease or development."


A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.